KR20200141986A - 개선된 길항성 항-인간 cd40 단클론 항체 - Google Patents

개선된 길항성 항-인간 cd40 단클론 항체 Download PDF

Info

Publication number
KR20200141986A
KR20200141986A KR1020207025757A KR20207025757A KR20200141986A KR 20200141986 A KR20200141986 A KR 20200141986A KR 1020207025757 A KR1020207025757 A KR 1020207025757A KR 20207025757 A KR20207025757 A KR 20207025757A KR 20200141986 A KR20200141986 A KR 20200141986A
Authority
KR
South Korea
Prior art keywords
ser
leu
val
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207025757A
Other languages
English (en)
Korean (ko)
Inventor
안톤 에그버트 피터 아당
보어 마크 드
Original Assignee
다이어비티스-프리, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이어비티스-프리, 인크. filed Critical 다이어비티스-프리, 인크.
Publication of KR20200141986A publication Critical patent/KR20200141986A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207025757A 2018-02-12 2019-02-11 개선된 길항성 항-인간 cd40 단클론 항체 Ceased KR20200141986A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18156288 2018-02-12
EP18156288.5 2018-02-12
PCT/NL2019/050086 WO2019156565A1 (en) 2018-02-12 2019-02-11 Improved antagonistic anti-human cd40 monoclonal antibodies

Publications (1)

Publication Number Publication Date
KR20200141986A true KR20200141986A (ko) 2020-12-21

Family

ID=61192786

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207025757A Ceased KR20200141986A (ko) 2018-02-12 2019-02-11 개선된 길항성 항-인간 cd40 단클론 항체

Country Status (8)

Country Link
US (2) US11396552B2 (https=)
EP (1) EP3752532A1 (https=)
JP (2) JP2021513367A (https=)
KR (1) KR20200141986A (https=)
CN (1) CN112119092A (https=)
AU (1) AU2019217207B2 (https=)
CA (1) CA3090322A1 (https=)
WO (1) WO2019156565A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025159610A1 (ko) * 2024-01-24 2025-07-31 서울대학교산학협력단 Cd40에 특이적으로 결합하는 항체 및 이의 용도

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
JP2021513367A (ja) * 2018-02-12 2021-05-27 ダイアベーツ−フリー， インコーポレイテッド 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体
CN115605594A (zh) * 2020-06-02 2023-01-13 帝人制药株式会社（Jp） 抗igf-1受体人源化抗体
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
CN115403670B (zh) * 2021-05-26 2026-03-10 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
WO2025122817A1 (en) * 2023-12-06 2025-06-12 The General Hospital Corporation Antagonistic cd40 antibodies
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4747825A (en) 1984-06-29 1988-05-31 Ferring Laboratories, Inc. Apparatus and methodology for pulsed administration of growth promoting agents
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
IT1178786B (it) 1984-12-21 1987-09-16 Assorenti Analoghi retro-inverso parzialmente modificati della neurotensina
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
US4723958A (en) 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4965251A (en) 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU649217B2 (en) 1988-11-18 1994-05-19 Regents Of The University Of California, The Method for site-specifically incorporating unnatural amino acids into proteins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
HUT71860A (en) 1992-08-27 1996-02-28 Deakin Res Ltd Retro-, inverso-, and retro-inverso synthetic peptide analogues
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5403590A (en) 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6339069B1 (en) 1996-10-15 2002-01-15 Elan Pharmaceuticalstechnologies, Inc. Peptide-lipid conjugates, liposomes and lipsomal drug delivery
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6103489A (en) 1997-03-21 2000-08-15 University Of Hawaii Cell-free protein synthesis system with protein translocation and processing
CA2303268A1 (en) 1997-06-13 1998-12-17 Scott Walsh Therapeutic nanospheres
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
FR2840307B1 (fr) 2002-05-30 2006-07-07 Centre Nat Rech Scient Nouvelles molecules multimeriques, leur procede de preparation, et leur utilisation pour la preparation de medicaments
WO2005006949A2 (en) 2003-07-07 2005-01-27 Wagner David H Methods for predicting development of auto-immune diseases and treatment of same
ATE447412T1 (de) * 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
US20080318837A1 (en) 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US7659252B2 (en) 2005-09-15 2010-02-09 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
US20070237826A1 (en) 2006-04-05 2007-10-11 Rao Kollipara K Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides
AR060487A1 (es) * 2006-04-21 2008-06-18 Xoma Technology Ltd Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
EP1854810A1 (en) * 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
EP2067785A1 (en) 2007-12-03 2009-06-10 Fresenius Medical Care Deutschland GmbH Human CD154-binding synthetic peptide and uses thereof
US8734786B2 (en) 2009-09-16 2014-05-27 Northwestern University Use of ECDI-fixed cell tolerance as a method for preventing allograft rejection
WO2011069037A2 (en) 2009-12-03 2011-06-09 The University Of North Carolina At Charlotte Stabilization and storage of biological pharmaceutical compositions
HUE049849T2 (hu) * 2010-03-31 2020-10-28 Boehringer Ingelheim Int Anti-CD40 antitestek
ES2957957T3 (es) 2010-10-19 2024-01-30 Op T Llc Péptidos para modular la actividad de linfocitos T y usos de los mismos
TR201909840T4 (tr) 2011-03-11 2019-07-22 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antikorları ve kullanımları.
CA2832281C (en) 2011-04-04 2019-11-05 Trustees Of Dartmouth College Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies
WO2012145632A1 (en) 2011-04-21 2012-10-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
KR101329411B1 (ko) 2012-05-31 2013-11-14 주식회사 엘지생활건강 피부투과성 펩타이드
EP3701969A1 (en) 2014-10-31 2020-09-02 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
CN107810198B (zh) * 2015-05-29 2021-09-03 艾伯维公司 抗cd40抗体及其用途
US20180172683A1 (en) 2015-06-22 2018-06-21 University Of Southern California Methods for analyzing the interaction between a target protein and a ligand
KR101810778B1 (ko) 2015-06-23 2017-12-20 서울대학교산학협력단 Cd154 결합 폴리펩타이드 및 그 용도
BR112018004296B1 (pt) 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos
JP2021513367A (ja) * 2018-02-12 2021-05-27 ダイアベーツ−フリー， インコーポレイテッド 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025159610A1 (ko) * 2024-01-24 2025-07-31 서울대학교산학협력단 Cd40에 특이적으로 결합하는 항체 및 이의 용도

Also Published As

Publication number Publication date
US11396552B2 (en) 2022-07-26
AU2019217207A1 (en) 2020-08-27
US20230059094A1 (en) 2023-02-23
AU2019217207B2 (en) 2025-12-18
JP2024024118A (ja) 2024-02-21
CA3090322A1 (en) 2019-08-15
US20210101991A1 (en) 2021-04-08
CN112119092A (zh) 2020-12-22
JP2021513367A (ja) 2021-05-27
WO2019156565A1 (en) 2019-08-15
EP3752532A1 (en) 2020-12-23

Similar Documents

Publication Publication Date Title
US11396552B2 (en) Antagonistic anti-human CD40 monoclonal antibodies
US20230201346A1 (en) Binding molecules specific for il-21 and uses thereof
JP6794448B2 (ja) 抗体サイトカイングラフト組成物および免疫調節のための使用方法
TW201806972A (zh) 雙特異性結合蛋白
CN108290949A (zh) 对asct2具有特异性的结合分子及其用途
MX2011004635A (es) Antagonistas de los receptores tipo toll 3.
CN108409860A (zh) 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用
JP2024512351A (ja) Ｇｄｆ－１５に対する抗体
KR102598319B1 (ko) 항-il-25 항체 및 그의 용도
CN104159610A (zh) 用于治疗代谢和心血管疾病的3型toll样受体拮抗剂
US20250270328A1 (en) Klrb1 binding agents and methods of use thereof
WO2022247826A1 (zh) 靶向pd-l1和cd73的特异性结合蛋白
HK40115111A (zh) 抗pilra抗体、其用途以及相关方法和试剂
RU2804456C1 (ru) Связывающие молекулы, специфичные к ил-21, и области их применения
EA052892B1 (ru) Антитела к альфа-рецептору интерлейкина-4 человека
HK40031443A (en) Binding molecules specific for il-21 and uses thereof
HK1230976A1 (en) Binding molecules specific for il-21 and uses thereof
HK1230976B (en) Binding molecules specific for il-21 and uses thereof
NZ725735B2 (en) Binding molecules specific for il-21 and uses thereof
BR112016029734B1 (pt) Anticorpo isolado ou fragmento de ligação ao antígeno deste e uso do mesmo, composição farmacêutica e método para detecção de níveis de expressão de il-21 em uma amostra

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B17 Application discontinued following pre-grant review

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B17-REX-PX0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601